Search research articles
Contact Us
Filters
Showing results (761-770 of 786) with videos related to
Page
of 79
Sort By:
European Urology
|
October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
The Lancet. Oncology
|
February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Reinhard Dummer, Jun Guo, Jason J Luke, et al.
The New England Journal of Medicine
|
March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Thomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Scientific Reports
|
January 22, 2024
Importance of dialysis specialists in early mortality in elderly hemodialysis patients: a multicenter retrospective cohort study
Yohan Park, Ji Won Lee, Se-Hee Yoon, et al.
Investigative and Clinical Urology
|
September 5, 2023
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
Seung-Hwan Jeong, Sang Eun Yeon, Su Youn Kim, et al.
Cancer Research and Treatment
|
October 14, 2025
Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13)
Jwa Hoon Kim, Sang Joon Shin, Woo Kyun Bae, et al.
BMC Nephrology
|
October 2, 2023
Effect of low-density lipoprotein level and mortality in older incident statin-naïve hemodialysis patients
Je Hun Song, Eun Hee Park, Jinsuk Bae, et al.
BMC Cancer
|
November 27, 2014
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
Seung Tae Kim, Yong Sang Hong, Ho Yeong Lim, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
October 16, 2025
Associations of Skeletal Muscle Mass and Body Mass Index With Clinical Outcomes in Autosomal-Dominant Polycystic Kidney Disease: An Observational Study
Dha Woon Im, Jiyun Jung, Miso Ha, et al.
Page
of 79
Search research articles
Search
Showing results (761-770 of 786) with videos related to
Sort By:
Page
of 79
European Urology
|
October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
The Lancet. Oncology
|
February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Reinhard Dummer, Jun Guo, Jason J Luke, et al.
The New England Journal of Medicine
|
March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Thomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Scientific Reports
|
January 22, 2024
Importance of dialysis specialists in early mortality in elderly hemodialysis patients: a multicenter retrospective cohort study
Yohan Park, Ji Won Lee, Se-Hee Yoon, et al.
Investigative and Clinical Urology
|
September 5, 2023
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
Seung-Hwan Jeong, Sang Eun Yeon, Su Youn Kim, et al.
Cancer Research and Treatment
|
October 14, 2025
Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13)
Jwa Hoon Kim, Sang Joon Shin, Woo Kyun Bae, et al.
BMC Nephrology
|
October 2, 2023
Effect of low-density lipoprotein level and mortality in older incident statin-naïve hemodialysis patients
Je Hun Song, Eun Hee Park, Jinsuk Bae, et al.
BMC Cancer
|
November 27, 2014
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
Seung Tae Kim, Yong Sang Hong, Ho Yeong Lim, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
October 16, 2025
Associations of Skeletal Muscle Mass and Body Mass Index With Clinical Outcomes in Autosomal-Dominant Polycystic Kidney Disease: An Observational Study
Dha Woon Im, Jiyun Jung, Miso Ha, et al.
Page
of 79